注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Eyenovia Inc是一家臨床階段的眼科公司 該公司正在開發基於其微劑量陣列打印(MAP)平台技術的療法。其產品管線專注於美國進行性近視的兒科患者和與年齡相關的近視力障礙或老花眼適應症的晚期治療適應症的研。該公司還在開髮用於散瞳的微劑量固定組合眼科藥物。該公司的候選產品包括MicroLine(用於老花眼)、MicroPine(用於進行性近視)和Mydcombi(用於散瞳)。MicroLine是毛果芸香鹼的微劑量版本,這是一種可以劑量依賴性地誘導瞳孔縮小或瞳孔收縮的眼科藥物。MicroPine是一種用於進行性近視(一種眼後部疾病)的局部治療藥物。Mydcombi是一種用於散瞳(眼睛擴張)的固定組合微製劑候選產品。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Michael M. Rowe | 60 | 2018 | CEO & Director |
Tsontcho Ianchulev | 48 | 2014 | Co-Founder, President, Chief Medical Officer & Non-Executive Chairman |
Charles E. Mather | 62 | 2018 | Independent Director |
Ram Palanki | - | 2022 | Independent Director |
James C. Tsai | - | - | Member of Scientific Advisory Board |
Louis R. Pasquale | - | - | Member of Scientific Advisory Board |
Douglas Fredrick | - | - | Member of Scientific Advisory Board |
April Jasper | - | 2019 | Member of Scientific Advisory Board |
Shan Lin | - | - | Member of Scientific Advisory Board |
Robert N. Weinreb | - | - | Member of Scientific Advisory Board |
Rachel Jacobson | 48 | 2022 | Independent Director |
Stephen K. Benjamin | 52 | 2022 | Independent Director |
Pamela F. Gallin | - | - | Member of Scientific Advisory Board |
Mark Bullimore | - | 2019 | Member of Scientific Advisory Board |
Ellen R. Strahlman | 65 | 2022 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核